1. Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y,
Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T.
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA
Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer
Models. Mol Cancer Ther. 2024 Mar 4;23(3):257-271. doi:
10.1158/1535-7163.MCT-23-0287. PMID: 38205802; PMCID: PMC10911705.
2. Meng M, Zhou H, He Y, Chen L, Wang W, Yang L, Wang Z, Zhang L, Wang S. CDH6
as a prognostic indicator and marker for chemotherapy in gliomas. Front Genet.
2022 Jul 22;13:949552. doi: 10.3389/fgene.2022.949552. PMID: 35938030; PMCID:
PMC9355303.
3. Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Sáez ME, Giagtzoglou N,
Cabrera-Socorro A, Bakker MHM, Ramirez A, Hankemeier T, Stomrud E, Mattsson-
Carlgren N, Scheltens P, van der Flier WM, Ikram MA, Malarstig A, Teunissen CE,
Amin N, van Duijn CM. CDH6 and HAGH protein levels in plasma associate with
Alzheimer's disease in APOE ε4 carriers. Sci Rep. 2020 May 19;10(1):8233. doi:
10.1038/s41598-020-65038-5. PMID: 32427856; PMCID: PMC7237496.